SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-067504
Filing Date
2023-03-10
Accepted
2023-03-10 15:22:00
Documents
13
Period of Report
2023-03-10
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K d354375d8k.htm   iXBRL 8-K 23249
5 GRAPHIC g354375g0311002004884.jpg GRAPHIC 2386
  Complete submission text file 0001193125-23-067504.txt   151559

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20230310.xsd EX-101.SCH 2890
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20230310_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20230310_pre.xml EX-101.PRE 11288
7 EXTRACTED XBRL INSTANCE DOCUMENT d354375d8k_htm.xml XML 3396
Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 23723331
SIC: 8071 Services-Medical Laboratories